Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DOLUTEGRAVIR Cause Agranulocytosis? 10 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 10 reports of Agranulocytosis have been filed in association with DOLUTEGRAVIR (Juluca). This represents 0.1% of all adverse event reports for DOLUTEGRAVIR.

10
Reports of Agranulocytosis with DOLUTEGRAVIR
0.1%
of all DOLUTEGRAVIR reports
2
Deaths
5
Hospitalizations

How Dangerous Is Agranulocytosis From DOLUTEGRAVIR?

Of the 10 reports, 2 (20.0%) resulted in death, 5 (50.0%) required hospitalization, and 2 (20.0%) were considered life-threatening.

Is Agranulocytosis Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for DOLUTEGRAVIR. However, 10 reports have been filed with the FAERS database.

What Other Side Effects Does DOLUTEGRAVIR Cause?

Foetal exposure during pregnancy (1,036) Exposure during pregnancy (776) Virologic failure (770) Pathogen resistance (586) Maternal exposure during pregnancy (517) Viral mutation identified (510) Treatment failure (453) Drug ineffective (447) Off label use (413) Blood hiv rna increased (410)

What Other Drugs Cause Agranulocytosis?

CLOZAPINE (1,766) CYCLOPHOSPHAMIDE (1,242) RITUXIMAB (1,154) SULFAMETHOXAZOLE\TRIMETHOPRIM (797) PANTOPRAZOLE (599) METHOTREXATE (550) SODIUM (549) EPIRUBICIN (491) METAMIZOLE (438) DOCETAXEL (436)

Which DOLUTEGRAVIR Alternatives Have Lower Agranulocytosis Risk?

DOLUTEGRAVIR vs DOLUTEGRAVIR\LAMIVUDINE DOLUTEGRAVIR vs DOLUTEGRAVIR\LAMIVUDINE\TENOFOVIR DISOPROXIL DOLUTEGRAVIR vs DOLUTEGRAVIR\RILPIVIRINE DOLUTEGRAVIR vs DOMPERIDONE DOLUTEGRAVIR vs DOMPERIDONE\PANTOPRAZOLE

Related Pages

DOLUTEGRAVIR Full Profile All Agranulocytosis Reports All Drugs Causing Agranulocytosis DOLUTEGRAVIR Demographics